Teva Pharmaceutical Industries Ltd. Reports Strong Q2 Results and Raises 2026 Outlook

Teva Pharmaceutical Industries Ltd. (TASE: TEVA) announced its second‑quarter 2026 earnings on 29 July 2026, delivering a mixed financial picture that nevertheless bolstered investor confidence and prompted a bullish revision of its full‑year guidance.

Revenue Performance

  • Total Q2 revenue: $4.1 billion, down 1 % YoY in U.S. dollars and 3 % in local currency (ILS), primarily due to a decline in generic‑product sales.
  • Innovative‑brand segment: Revenues surged 43 % YoY in local currency to over $1 billion, underscoring the strength of Teva’s branded pipeline.
  • Key brands driving growth:
  • AUSTEDO – projected 2026 revenue of $2.45 billion–$2.6 billion.
  • AJOVY – projected 2026 revenue of $850 million–$870 million.
  • UZEDY – Q2 net sales of $77 million, up 43 % YoY, with a revised 2026 outlook of $270 million–$290 million (previously $250 million–$280 million).

Earnings and Guidance

  • Despite a miss on earnings estimates, Teva’s revenue guidance exceeded analyst expectations.
  • The company raised its 2026 revenue midpoint by $75 million, reflecting confidence in the continued momentum of its innovative portfolio.
  • Analysts noted that Teva’s “innovation engine offsets the generics slump,” with particular enthusiasm for the surge in AJOVY sales, prompting some to describe the performance as “shocked.”

Market Reaction

  • Shares surged following the earnings announcement, with a significant lift on the Tel Aviv Stock Exchange (TASE) despite broader market pressure.
  • The stock’s rally was amplified by positive sentiment around a potential direct listing on the New York Stock Exchange (NYSE), a move that could unlock additional capital and liquidity for the company.

Strategic Context

  • Teva’s pivot to a growth‑oriented strategy has been evident since its decision to prioritize branded, high‑margin products over lower‑margin generics.
  • The company’s $40 billion comeback narrative—highlighted in a recent Calcalist Tech feature—frames Teva as a resurgence story within the global pharmaceutical landscape.
  • The inflammatory bowel disease (IBD) market is projected to grow sharply through 2036, driven by next‑generation therapies targeting IL‑23, TL1A, and S1P pathways. Teva’s UZEDY is positioned to capture a share of this expanding therapeutic arena, benefiting from the rising prevalence of Crohn’s disease and ulcerative colitis.

Bottom Line

Teva’s Q2 2026 results demonstrate a robust rebound in its innovative drug portfolio even as generic revenues lag. The company’s revised outlook and potential NYSE listing signal a renewed focus on high‑growth opportunities. For investors, the combination of strong brand performance, upward‑revised guidance, and strategic market positioning paints a compelling picture of Teva’s trajectory toward sustained profitability and global market relevance.